Clinical Trial

Post-acute COVID-19 Sequelae in Denmark

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 12, 2025 (before its estimated March 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Since the first SARS-CoV-2 cases in 2019, over 660 million COVID-19 cases have been reported globally, including 183 million in the EU. Up to 70% of those infected experience reduced organ function four months or more after a COVID-19 diagnosis, potentially increasing the risk of non-communicable diseases (NCDs). The post-acute phase (PAP) after COVID-19 (four months or more after the acute phase) can lead to impaired function in various organ systems, with a focus on the lungs, cardiovascular system, and kidneys. These three NCDs collectively impose a significant burden on individuals and society. Urgently, we need to understand the connection between COVID-19, PAP and NCDs, identifying robust biomarkers for early detection. This study examines PAP and associated risk factors, investigating the link between PAP and the heightened risk of lung, heart, and kidney complications. Utilizing data from a cohort of COVID-19 patients and a control group with respiratory diseases, the study aims to determine prevalence and risk ratios more precisely. The aim is to contribute to minimizing the risk of NCD development or exacerbation in current and future COVID-19 patients, enhancing our understanding of chronic disease development at the population leve
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-01-03.
Status change: Not Yet Recruiting → Recruiting 2025-03-06
Trial Details
NCT Number NCT06191302
Lead Sponsor Hvidovre University Hospital
Conditions Non-communicable Disease, COVID-19
Enrollment 800 participants
Start Date 2024-09-10
Primary Completion 2026-03-01 (estimated)
Study Completion 2026-03-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-12